SI2437753T1 - Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo - Google Patents

Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo

Info

Publication number
SI2437753T1
SI2437753T1 SI201031333A SI201031333A SI2437753T1 SI 2437753 T1 SI2437753 T1 SI 2437753T1 SI 201031333 A SI201031333 A SI 201031333A SI 201031333 A SI201031333 A SI 201031333A SI 2437753 T1 SI2437753 T1 SI 2437753T1
Authority
SI
Slovenia
Prior art keywords
compositions containing
vaccine compositions
glucopyranosyl lipid
lipid adjuvants
synthetic glucopyranosyl
Prior art date
Application number
SI201031333A
Other languages
English (en)
Inventor
Steven G. Reed
Darrick Carter
Original Assignee
Infectious Disease Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infectious Disease Research Institute filed Critical Infectious Disease Research Institute
Publication of SI2437753T1 publication Critical patent/SI2437753T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
SI201031333A 2009-06-05 2010-06-04 Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo SI2437753T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18470309P 2009-06-05 2009-06-05
EP10784178.5A EP2437753B1 (en) 2009-06-05 2010-06-04 Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
PCT/US2010/037466 WO2010141861A1 (en) 2009-06-05 2010-06-04 Synthetic glucopyranosyl lipid adjuvants

Publications (1)

Publication Number Publication Date
SI2437753T1 true SI2437753T1 (sl) 2016-12-30

Family

ID=43298190

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201031333A SI2437753T1 (sl) 2009-06-05 2010-06-04 Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo

Country Status (21)

Country Link
US (4) US8722064B2 (sl)
EP (2) EP2437753B1 (sl)
JP (3) JP5830015B2 (sl)
CN (2) CN105131051B (sl)
AU (1) AU2010256461B2 (sl)
CA (1) CA2764374C (sl)
CY (1) CY1118347T1 (sl)
DK (1) DK2437753T3 (sl)
ES (1) ES2606563T3 (sl)
HR (1) HRP20161585T1 (sl)
HU (1) HUE031051T2 (sl)
IL (2) IL216669A (sl)
LT (1) LT2437753T (sl)
MX (2) MX2011012836A (sl)
PL (1) PL2437753T3 (sl)
PT (1) PT2437753T (sl)
RU (3) RU2560182C2 (sl)
SI (1) SI2437753T1 (sl)
SM (1) SMT201600437B (sl)
TW (2) TWI549688B (sl)
WO (1) WO2010141861A1 (sl)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2068918B1 (en) 2006-09-26 2012-05-02 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
BRPI0923225A2 (pt) 2008-12-02 2016-10-04 Chiralgen Ltd metodo para sintese de acidos nucleicos modificados no atomo de fosforo
EP2437753B1 (en) 2009-06-05 2016-08-31 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
BR112012022939A2 (pt) 2010-03-11 2016-08-02 Immune Design Corp composição farmacêutica para uso em um método de imunização de um indivíduo em necessidade do mesmo contra um vírus influenza
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ 不斉補助基
AU2012217723A1 (en) 2011-02-15 2013-08-29 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
US9044420B2 (en) 2011-04-08 2015-06-02 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2012149307A2 (en) 2011-04-27 2012-11-01 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
WO2013012758A1 (en) 2011-07-19 2013-01-24 Ontorii, Inc. Methods for the synthesis of functionalized nucleic acids
EP2780350B1 (en) * 2011-11-18 2019-03-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
ES2894724T3 (es) 2011-12-02 2022-02-15 Rhode Island Hospital Vacuna contra la malaria falciparum
US11510875B2 (en) 2012-02-07 2022-11-29 Access To Advanced Health Institute Adjuvant formulations comprising TLR4 agonists and methods of using the same
JP5650780B2 (ja) 2012-04-04 2015-01-07 日東電工株式会社 ワクチン組成物
EP3388835B1 (en) 2012-05-16 2020-04-01 Immune Design Corp. Vaccines for hsv-2
EP2858722B8 (en) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
CN104684893B (zh) 2012-07-13 2016-10-26 日本波涛生命科学公司 不对称辅助基团
RU2677639C2 (ru) * 2012-07-13 2019-01-18 Шин Ниппон Биомедикал Лэбораториз, Лтд. Хиральный адъювант нуклеиновой кислоты
KR102450907B1 (ko) 2012-07-13 2022-10-04 웨이브 라이프 사이언시스 리미티드 키랄 제어
BR112015013440B1 (pt) 2012-12-13 2020-12-08 Aduro Biotech, Inc composições compreendendo dinucleotídeos de purina cíclicos com estereoquímicas
US8957047B2 (en) 2013-04-18 2015-02-17 Immune Design Corp. GLA monotherapy for use in cancer treatment
TN2015000457A1 (en) 2013-04-29 2017-04-06 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
ES2822584T3 (es) 2013-05-03 2021-05-04 Univ California Inducción de dinucleótidos cíclicos del interferón tipo I
JP6453855B2 (ja) 2013-05-18 2019-01-16 アドゥロ バイオテック，インク． 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2015017652A1 (en) 2013-07-31 2015-02-05 Memorial Sloan-Kettering Cancer Center Sting crystals and modulators
CN105517555A (zh) * 2013-09-05 2016-04-20 免疫设计股份有限公司 针对药物成瘾的疫苗组合物
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9962439B2 (en) 2013-10-03 2018-05-08 Nitto Denko Corporation Injectable vaccine composition
CN105530954A (zh) 2013-10-03 2016-04-27 日东电工株式会社 鼻粘膜疫苗组合物
CN105530958A (zh) 2013-10-03 2016-04-27 日东电工株式会社 粘膜疫苗组合物
RU2016109150A (ru) 2013-10-03 2017-11-10 Нитто Денко Корпорейшн Мукозальная вакцинная композиция
AU2014373928C1 (en) 2013-12-31 2020-12-17 Access To Advanced Health Institute Single vial vaccine formulations
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
KR20230152178A (ko) 2014-01-16 2023-11-02 웨이브 라이프 사이언시스 리미티드 키랄 디자인
SG11201605883UA (en) * 2014-01-21 2016-08-30 Immune Design Corp Compositions for use in the treatment of allergic conditions
JP6581101B2 (ja) 2014-02-14 2019-09-25 イミューン デザイン コーポレイション 局所免疫刺激及び全身免疫刺激の組み合わせによる癌の免疫療法
JP2017522312A (ja) 2014-07-15 2017-08-10 イミューン デザイン コーポレイション Ｔｌｒ４アゴニストアジュバント及びレンチウイルスベクターを用いたプライム・ブーストレジメン
AR103894A1 (es) 2015-03-10 2017-06-14 Aduro Biotech Inc Composiciones y métodos para activar la señalización dependiente del estimulador del gen interferón
TW201722472A (zh) 2015-11-27 2017-07-01 Nitto Denko Corp 口腔內投與用疫苗醫藥組合物及口腔內投與用疫苗醫藥組合物之製造方法
MX2018013640A (es) 2016-05-16 2019-08-01 Infectious Disease Res Inst Liposomas pegiladas y metodos de uso.
HUE059605T2 (hu) 2016-05-16 2022-11-28 Access To Advanced Health Inst TLR agonista tartalmú készítmény és használati eljárások
US20200148729A1 (en) 2016-05-21 2020-05-14 Infectious Disease Research Institute Compositions and Methods for Treating Secondary Tuberculosis and Nontuberculosis Mycobacterium Infections
US11173126B2 (en) 2016-06-01 2021-11-16 Infectious Disease Research Institute Nanoalum particles comprising a PAA sizing agent
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
EP3522893A4 (en) * 2016-10-04 2020-08-26 University Of Maryland, Baltimore METHODS OF TREATMENT OF SEPTICEMIA USING LIPID A-BASED THERAPEUTIC AGENTS (ASLA) ANTISEPSY
US10874734B2 (en) * 2016-11-25 2020-12-29 Mogam Institute For Biomedical Research Varicella zoster virus vaccine
CN110198736B (zh) 2016-12-26 2023-12-22 财团法人牧岩生命科学研究所 带状疱疹疫苗组合物
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3638207A1 (en) 2017-06-15 2020-04-22 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
AU2018330165A1 (en) 2017-09-08 2020-04-02 Access To Advanced Health Institute Liposomal formulations comprising saponin and methods of use
JP2020533354A (ja) 2017-09-13 2020-11-19 サノフィ・パスツールＳａｎｏｆｉ Ｐａｓｔｅｕｒ ヒトサイトメガロウイルス免疫原性組成物
IL276608B2 (en) 2018-02-12 2024-04-01 Inimmune Corp TOLL-like receptor ligands
WO2019175145A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against urinary tract infections
MX2021011418A (es) 2019-03-18 2021-10-13 Janssen Pharmaceuticals Inc Metodos de produccion de bioconjugados de polisacaridos de e. coli o- antigeno, sus composiciones y metodos de utilizacion.
US11446370B2 (en) 2019-03-18 2022-09-20 Janssen Pharmaceuticals, Inc. Bioconjugates of E. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
KR20220125149A (ko) 2019-05-25 2022-09-14 액세스 투 어드밴스드 헬스 인스티튜트 애주번트 백신 에멀션을 분무 건조시키기 위한 조성물 및 방법
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
KR20220107166A (ko) 2019-10-02 2022-08-02 얀센 백신스 앤드 프리벤션 비.브이. 스타필로코커스 펩티드 및 사용 방법
WO2021097347A1 (en) 2019-11-15 2021-05-20 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
BR112022013720A2 (pt) 2020-01-16 2022-10-11 Janssen Pharmaceuticals Inc Mutante fimh, composições com o mesmo e seu uso
AU2021241355A1 (en) 2020-03-23 2022-10-13 Hdt Bio Corp. Compositions and methods for delivery of RNA
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
KR20230043157A (ko) 2020-09-17 2023-03-30 얀센 파마슈티칼즈, 인코포레이티드 다가 백신 조성물 및 이의 용도
CA3200234A1 (en) 2020-11-25 2022-06-02 Daryl C. Drummond Lipid nanoparticles for delivery of nucleic acids, and related methods of use
US20240050561A1 (en) 2020-12-23 2024-02-15 Access To Advanced Health Institute Solanesol vaccine adjuvants and methods of preparing same
KR20230125842A (ko) 2021-01-12 2023-08-29 얀센 파마슈티칼즈, 인코포레이티드 FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도
BR112023019874A2 (pt) 2021-04-01 2023-11-07 Janssen Pharmaceuticals Inc Produção de bioconjugados de e. coli o18
WO2022256740A1 (en) 2021-06-04 2022-12-08 Curia Ip Holdings, Llc Polymeric fusion proteins and compositions for inducing an immune response against infection

Family Cites Families (244)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4029762A (en) * 1971-11-17 1977-06-14 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Lipid A-preparation
US4286592A (en) 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4420558A (en) 1981-02-12 1983-12-13 Janssen Pharmaceutica N.V. Bright field light microscopic method of enumerating and characterizing subtypes of white blood cells and their precursors
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4420461A (en) 1982-05-26 1983-12-13 Ortho Diagnostic Systems Inc. Agglutination-inhibition test kit for detecting immune complexes
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4743540A (en) 1983-09-27 1988-05-10 Memorial Sloan-Kettering Cancer Center Method for diagnosis of subclassifications of common varied immunodeficiency disease group
US5147785A (en) 1983-11-01 1992-09-15 Amtl Corporation Method and apparatus for measuring the degree of reaction between a foreign entity and white blood cells
US4614722A (en) 1983-11-01 1986-09-30 Pasula Mark J Method and apparatus for measuring the degree of reaction between antigens and leukocyte cellular antibodies
US4595654A (en) 1983-11-07 1986-06-17 Immunomedics Inc. Method for detecting immune complexes in serum
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US4629722A (en) 1984-07-12 1986-12-16 Ribi Immunochem Research, Inc. Method of inhibiting the onset of acute radiation syndrome
US5612041A (en) * 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
JPS6153295A (ja) 1984-08-24 1986-03-17 Dai Ichi Seiyaku Co Ltd ジサツカライド誘導体
US5066794A (en) * 1984-08-24 1991-11-19 Daiichi Pharmaceutical Co., Ltd. Process for preparing a disaccharide derivative
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4659659A (en) 1985-01-22 1987-04-21 Monsanto Company Diagnostic method for diseases having an arthritic component
GB8508845D0 (en) * 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4746742A (en) 1985-11-28 1988-05-24 Toho Yakuhin Kogyo Kabushiki Kaisha Analogs of nonreducing monosaccharide moiety of lipid A
US6514691B1 (en) 1986-01-22 2003-02-04 Institut Pasteur Peptides of human immunodeficiency virus type 2 (HIV-2), antibodies against peptides of HIV-2, and methods and kits for detecting HIV-2
US5310651A (en) 1986-01-22 1994-05-10 Institut Pasteur DNA probes of human immunodeficiency virus type 2 (HIV-2), and methods employing these probes for dectecting the presence of HIV-2
US6544728B1 (en) * 1986-01-22 2003-04-08 Institut Pasteur Methods and kits for diagnosing human immunodeficiency virus type 2 (HIV-2), proteins of HIV-2, and vaccinating agents for HIV-2
US6054565A (en) * 1986-03-03 2000-04-25 Institut Pasteur Nucleic Acids of HIV-2, Diagnostic Test Kit and Method using Nucleic Acid Probes of HIV-2
US5169763A (en) 1986-04-08 1992-12-08 Transgene S.A., Institut Pasteur Viral vector coding glycoprotein of HIV-1
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
JPH0755906B2 (ja) 1986-07-01 1995-06-14 第一製薬株式会社 ジサツカライド誘導体含有鎮痛剤
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US4948587A (en) 1986-07-08 1990-08-14 Massachusetts Institute Of Technology Ultrasound enhancement of transbuccal drug delivery
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
FR2672290B1 (fr) 1991-02-05 1995-04-21 Pasteur Institut Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
US5565209A (en) 1987-03-17 1996-10-15 Akzo Nobel N.V. Adjuvant mixture
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP0304578B1 (en) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
US4780212A (en) 1987-07-31 1988-10-25 Massachusetts Institute Of Technology Ultrasound enchancement of membrane permeability
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
EP0324455A3 (en) 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
GB2232892B (en) 1988-02-23 1991-07-24 John Mark Tucker Occlusive body for administering a physiologically active substance
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5888519A (en) 1988-06-02 1999-03-30 The United States Of America As Represented By The Secretary Of The Army Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
US5231168A (en) * 1988-09-16 1993-07-27 Statens Seruminstitut Malaria antigen
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
ES2160570T3 (es) 1988-12-16 2001-11-16 Nederlanden Staat Mutantes de neumolisina y vacunas de neumococos fabricadas a partir de los mismos.
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
DK0382271T3 (da) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoler som adjuvanser i vacciner
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649012B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
FR2649013B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
ES2109921T3 (es) 1989-07-25 1998-02-01 Smithkline Beecham Biolog Nuevos antigenos y procedimientos para su preparacion.
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US4981684A (en) 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
US6120769A (en) 1989-11-03 2000-09-19 Immulogic Pharmaceutical Corporation Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
US5298396A (en) 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5124141A (en) * 1990-06-14 1992-06-23 Flow Incorporated Method for diagnosing malaria
US5162990A (en) 1990-06-15 1992-11-10 The United States Of America As Represented By The United States Navy System and method for quantifying macrophage phagocytosis by computer image analysis
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
DE122007000018I1 (de) 1991-07-19 2007-05-24 Univ Queensland Polynukleotidabschnitt des HPV16-Genoms
US5464387A (en) 1991-07-24 1995-11-07 Alza Corporation Transdermal delivery device
US5585103A (en) 1991-07-25 1996-12-17 Idec Pharmaceutical Corporation Induction of cytotoxic T-lymphocyte responses
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
DE69207603T2 (de) 1991-08-16 1996-09-12 Vical Inc Zusammensetzung und verfahren zur behandlung von zystischer fibrose
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
WO1993010152A1 (en) 1991-11-16 1993-05-27 Smithkline Beecham Biologicals S.A. HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG
US6057427A (en) 1991-11-20 2000-05-02 Trustees Of Dartmouth College Antibody to cytokine response gene 2(CR2) polypeptide
JP3723231B2 (ja) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
US5286718A (en) 1991-12-31 1994-02-15 Ribi Immunochem Research, Inc. Method and composition for ameliorating tissue damage due to ischemia and reperfusion
JPH05328975A (ja) 1992-06-02 1993-12-14 Takara Shuzo Co Ltd Ｅ１ａ−ｆ遺伝子
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
JPH09507741A (ja) 1992-06-10 1997-08-12 アメリカ合衆国 ヒト血清による不活性化に耐性のあるベクター粒子
WO1994000152A1 (en) 1992-06-25 1994-01-06 Georgetown University Papillomavirus vaccines
SG49909A1 (en) 1992-06-25 1998-06-15 Smithkline Beecham Biolog Vaccine composition containing adjuvants
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5411865A (en) 1993-01-15 1995-05-02 Iasys Corporation Method of detecting anti-leishmania parasite antibodies
PT1618888E (pt) 1993-03-09 2011-04-08 Univ Rochester Produção de proteína da cápside de vírus de papiloma humano e partículas semelhantes a vírus
CN1087176C (zh) 1993-03-23 2002-07-10 史密斯克莱·比奇曼生物公司 含有3－o脱酰基单磷酰脂a的疫苗制剂
US5532133A (en) 1993-06-02 1996-07-02 New York University Plasmodium vivax blood stage antigens, PvESP-1, antibodies, and diagnostic assays
US6106824A (en) 1993-08-13 2000-08-22 The Rockefeller University Expression of growth associated protein B-50/GAP-43 in vitro and in vivo
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
EP0892445B1 (en) 1993-11-02 2004-04-07 Matsushita Electric Industrial Co., Ltd. Semiconductor device comprising an aggregate of semiconductor micro-needles
US5814599A (en) * 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5458140A (en) 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
HU219810B (hu) 1993-11-17 2001-08-28 Deutsche Om Arzneimittel Gmbh. Glükózamin-diszacharidok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények, valamint alkalmazásuk
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5457041A (en) 1994-03-25 1995-10-10 Science Applications International Corporation Needle array and method of introducing biological substances into living cells using the needle array
US5591139A (en) * 1994-06-06 1997-01-07 The Regents Of The University Of California IC-processed microneedles
PT772619E (pt) 1994-07-15 2006-10-31 Univ Iowa Res Found Oligonucleotidos imunomoduladores
US7037712B2 (en) 1994-07-26 2006-05-02 Commonwealth Scientific And Industrial Research Organisation DNA encoding ovine adenovirus (OAV287) and its use as a viral vector
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
SE9403137D0 (sv) 1994-09-20 1994-09-20 Perstorp Ab Derivatives of carbohydrates and compositions containing them
AU4270196A (en) 1994-10-07 1996-05-02 Lutz Gissmann Papilloma virus-like particles, fusion proteins and process for producing the same
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2727689A1 (fr) * 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
EP0808630B1 (en) 1995-02-08 2004-09-01 Takara Bio Inc. Cancer control
EP0812358A1 (en) 1995-02-24 1997-12-17 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US5912166A (en) 1995-04-21 1999-06-15 Corixa Corporation Compounds and methods for diagnosis of leishmaniasis
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US6417172B1 (en) * 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
US5993800A (en) 1995-06-05 1999-11-30 Bristol-Myers Squibb Company Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US6309847B1 (en) 1995-07-05 2001-10-30 Yeda Research And Development Co. Ltd. Method for detecting or monitoring the effectiveness of treatment of T cell mediated diseases
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
WO1997011708A1 (en) 1995-09-29 1997-04-03 Eisai Research Institute Method for treating alcoholic liver disease
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5618275A (en) * 1995-10-27 1997-04-08 Sonex International Corporation Ultrasonic method and apparatus for cosmetic and dermatological applications
US5843462A (en) 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
US5846758A (en) 1995-11-30 1998-12-08 His Excellency Ghassan I. Shaker Method for diagnosing autoimmune diseases
SE9600648D0 (sv) 1996-02-21 1996-02-21 Bror Morein Receptorbimdande enhet
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
WO1998001139A1 (en) 1996-07-03 1998-01-15 Eisai Co., Ltd. Injections containing lipid a analogues and process for the preparation thereof
CA2265889A1 (en) 1996-09-06 1998-03-12 The Regents Of The University Of California E25a protein, methods for production and use thereof
US5955306A (en) 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
CA2268825C (en) 1996-10-11 2006-04-18 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
JPH10131046A (ja) 1996-10-29 1998-05-19 Nikka Chem Co Ltd 繊維の耐久性ｐＨ緩衝加工方法
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US7033598B2 (en) 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
DE19654221B4 (de) 1996-12-23 2005-11-24 Telefonaktiebolaget Lm Ericsson (Publ) Leitungsanschlußschaltkreis
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
US6977073B1 (en) 1997-02-07 2005-12-20 Cem Cezayirli Method for stimulating an immune response
JP3844366B2 (ja) 1997-02-25 2006-11-08 コリクサ コーポレイション 前立腺ガンの免疫診断のための化合物およびそれらの使用方法
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
JP5019494B2 (ja) 1997-04-01 2012-09-05 コリクサ コーポレーション モノホスホリルリピドａの水性免疫アジュバント組成物
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
US6358508B1 (en) 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
WO1998058956A2 (en) 1997-06-23 1998-12-30 Ludwig Institute For Cancer Research Methods for inducing an immune response involving prime-boost protocols
WO1999003884A2 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
ATE435661T1 (de) 1997-08-29 2009-07-15 Antigenics Inc Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6749856B1 (en) * 1997-09-11 2004-06-15 The United States Of America, As Represented By The Department Of Health And Human Services Mucosal cytotoxic T lymphocyte responses
US6368604B1 (en) * 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
CN1280619A (zh) 1997-11-28 2001-01-17 根瑟特公司 沙眼衣原体的基因组序列和多肽,其片段以及其用途,特别是用于诊断、预防和治疗感染
US7012134B2 (en) 1998-01-26 2006-03-14 Human Genome Sciences, Inc. Dendritic enriched secreted lymphocyte activation molecule
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
SI1659179T1 (sl) 1998-02-05 2011-10-28 Glaxosmithkline Biolog Sa S tumorjem povezani antigenski derivati iz MAGE druĹľine in zaporedja nukleinskih kislin, ki jih kodirajo, uporabni za pripravo fuzijskih proteinov in sestavkov za cepljenje
US6488936B1 (en) 1998-02-12 2002-12-03 Wyeth Immunogenic composition of interleukin-12 (IL-12), alum, herpes simplex viral (HSV) antigen, and method thereof
US6596501B2 (en) * 1998-02-23 2003-07-22 Fred Hutchinson Cancer Research Center Method of diagnosing autoimmune disease
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
WO1999045957A2 (en) 1998-03-09 1999-09-16 Smithkline Beecham Biologicals S.A. Combined vaccine compositions
CZ302870B6 (cs) 1998-04-07 2011-12-28 Corixa Corporation Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou
GB2336310B (en) 1998-04-14 2003-09-10 Stowic Resources Ltd Method of manufacturing transdermal patches
EP1073734B1 (en) 1998-04-15 2009-09-23 Ludwig Institute for Cancer Research Ltd. Tumor associated nucleic acids and uses therefor
US6680175B2 (en) * 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
ES2296390T3 (es) 1998-05-07 2008-04-16 Corixa Corporation Composicion coadyuvante y procedimiento para su uso.
US6322532B1 (en) 1998-06-24 2001-11-27 3M Innovative Properties Company Sonophoresis method and apparatus
TW200728465A (en) 1998-07-14 2007-08-01 Corixa Corp Compositions and methods for the therapy and diagnosis of prostate cancer
WO2000010375A1 (en) 1998-08-25 2000-03-02 Gallenberg Ronald J Beach cleaning apparatus and method
EP1111390A4 (en) 1998-09-01 2007-11-14 Eisai R&D Man Co Ltd METHOD FOR EVALUATING INJECTIONS CONTAINING LIPID A ANALOGS
US6692752B1 (en) * 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
JP2000095694A (ja) * 1998-09-24 2000-04-04 Sankyo Co Ltd 新規な医療用薬剤
WO2000018929A2 (en) 1998-09-25 2000-04-06 Smithkline Beecham Biologicals S.A. Paramyxovirus vaccines
US6375944B1 (en) * 1998-09-25 2002-04-23 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
US7001770B1 (en) 1998-10-15 2006-02-21 Canji, Inc. Calpain inhibitors and their applications
TR200101055T2 (tr) * 1998-10-16 2001-09-21 Smithkline Beecham Biologicals S.A. Adjuvan sistemler ve aşılar
US6261573B1 (en) 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
US6512102B1 (en) 1998-12-31 2003-01-28 Chiron Corporation Compositions and methods of diagnosis and treatment using casein kinase I
WO2000042994A2 (en) 1999-01-21 2000-07-27 North Shore-Long Island Jewish Research Institute Inhibition of bacterial dissemination
AU769539B2 (en) * 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US20030170249A1 (en) 1999-02-19 2003-09-11 Hakomori Sen-Itiroh Vaccines directed to cancer-associated carbohydrate antigens
US6770445B1 (en) 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
GB9906177D0 (en) 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
CA2369883A1 (en) 1999-04-07 2000-10-19 Hitachi Chemical Co., Ltd. Method for judging autoimmune disease, method for detecting anti-reg protein autoantibody and diagnostics for autoimmune diseases
ES2228497T3 (es) 1999-04-19 2005-04-16 Glaxosmithkline Biologicals S.A. Composicion adyuvante que comprende saponina y un oligonucleotido inmunoestimulante.
US6685699B1 (en) 1999-06-09 2004-02-03 Spectrx, Inc. Self-removing energy absorbing structure for thermal tissue ablation
AU6884200A (en) 1999-08-26 2001-03-19 Biovitrum Ab Novel response element
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US7084256B2 (en) 1999-09-24 2006-08-01 Large Scale Biology Corporation Self antigen vaccines for treating B cell lymphomas and other cancers
JP4162813B2 (ja) 1999-10-28 2008-10-08 久光製薬株式会社 イオントフォレーシス装置
US6218186B1 (en) 1999-11-12 2001-04-17 Trustees Of The University Of Pennsylvania HIV-MSCV hybrid viral vector for gene transfer
CA2396744C (en) 1999-11-15 2011-07-12 Biomira, Inc. Synthetic lipid-a analogs and uses thereof
US20020064801A1 (en) 1999-12-01 2002-05-30 Ryan Jeffrey R. Novel and practical serological assay for the clinical diagnosis of leishmaniasis
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
US6587792B1 (en) * 2000-01-11 2003-07-01 Richard A. Thomas Nuclear packing efficiency
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
AU2001233132A1 (en) 2000-01-31 2001-08-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Hybrid adeno-retroviral vector for the transfection of cells
EP1122542A1 (en) 2000-02-01 2001-08-08 Anda Biologicals S.A. Method for the rapid detection of whole microorganisms on retaining membranes by use of chaotropic agents
WO2001062893A2 (en) 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
EP1284740B1 (en) 2000-05-19 2008-05-21 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with monosaccharide-based compounds
WO2001092550A2 (en) 2000-05-31 2001-12-06 Human Gene Therapy Research Institute Methods and compositions for efficient gene transfer using transcomplementary vectors
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US6969704B1 (en) 2000-08-25 2005-11-29 The Trustees Of Columbia University In The City Of New York Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject
US7060802B1 (en) 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
EP1341546B1 (en) 2000-10-06 2011-09-21 The Symbio Herborn Group GmbH u.Co Kyberdrug as autovaccines with immune-regulating effects
JP2004511527A (ja) 2000-10-18 2004-04-15 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム ワクチン
WO2002058727A2 (en) 2001-01-26 2002-08-01 Walter Reed Army Institute Of Research Recombinant plasmodium falciparum merozoite protein-1/42 vaccine
US6893820B1 (en) 2001-01-31 2005-05-17 The Ohio State University Research Foundation Detection of methylated CpG rich sequences diagnostic for malignant cells
US7029685B2 (en) * 2001-03-26 2006-04-18 The United States Of America As Represented By The Secretary Of The Army Plasmodium falciparum AMA-1 protein and uses thereof
CA2441952C (en) * 2001-03-26 2010-06-01 Walter Reed Army Institute Of Research Plasmodium falciparum ama-1 protein and uses thereof
US6933123B2 (en) 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
US6844192B2 (en) * 2001-06-29 2005-01-18 Wake Forest University Adenovirus E4 protein variants for virus production
US7727974B2 (en) * 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
WO2003021227A2 (en) 2001-09-05 2003-03-13 The Children's Hospital Of Philadelphia Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US6752995B2 (en) 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
US6908453B2 (en) 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
US6911434B2 (en) * 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
RU2288723C2 (ru) * 2002-02-04 2006-12-10 Корикса Корпорейшн Профилактическое и терапевтическое лечение инфекционных и других заболеваний с помощью иммуноэффективных соединений
JP2005523902A (ja) 2002-02-04 2005-08-11 コリクサ コーポレイション 感染症及び他の疾患の免疫効果化合物による予防及び治療処理
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
EP1549322B1 (en) 2002-05-09 2010-02-17 Oncothyreon Inc. Lipid a and other carbohydrate ligand analogs
US7018345B2 (en) 2002-12-06 2006-03-28 Hisamitsu Pharmaceutical Co., Inc. Iontophoresis system
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
FR2862062B1 (fr) 2003-11-06 2005-12-23 Oreal Lipide a et composition topique, notamment cosmetique, le comprenant
EP2068918B1 (en) * 2006-09-26 2012-05-02 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2009035528A2 (en) * 2007-09-07 2009-03-19 University Of Georgia Research Foundation, Inc. Synthetic lipid a derivative
KR101064518B1 (ko) 2007-09-21 2011-09-19 주식회사 운화 저장근을 가지는 초본식물의 형성층 유래 식물줄기세포주 및 이의 분리방법
US9930541B2 (en) 2007-12-27 2018-03-27 Nokia Technologies Oy Maintaining the integrity of configuration information of a network of access points for use in positioning an apparatus
EP2437753B1 (en) * 2009-06-05 2016-08-31 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
US11510875B2 (en) 2012-02-07 2022-11-29 Access To Advanced Health Institute Adjuvant formulations comprising TLR4 agonists and methods of using the same
JP5328975B2 (ja) 2012-12-19 2013-10-30 ルネサスエレクトロニクス株式会社 Ｒｆパワーモジュール
US8957047B2 (en) * 2013-04-18 2015-02-17 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis

Also Published As

Publication number Publication date
SMT201600437B (it) 2017-01-10
CN102481312A (zh) 2012-05-30
DK2437753T3 (en) 2016-12-19
JP2017137327A (ja) 2017-08-10
US8722064B2 (en) 2014-05-13
HUE031051T2 (en) 2017-06-28
RU2020129844A (ru) 2022-03-10
LT2437753T (lt) 2016-12-12
RU2015129468A3 (sl) 2019-01-21
RU2015129468A (ru) 2015-12-27
IL216669A (en) 2016-04-21
CN102481312B (zh) 2015-07-15
MX2011012836A (es) 2012-04-20
EP3124491B1 (en) 2019-10-30
ES2606563T3 (es) 2017-03-24
CA2764374A1 (en) 2010-12-09
WO2010141861A1 (en) 2010-12-09
EP2437753A4 (en) 2012-12-05
JP2012528892A (ja) 2012-11-15
US9480740B2 (en) 2016-11-01
JP6251431B2 (ja) 2017-12-20
PL2437753T3 (pl) 2017-03-31
MX360448B (es) 2018-11-01
BRPI1011072A2 (pt) 2016-04-12
US20180028649A1 (en) 2018-02-01
EP2437753A1 (en) 2012-04-11
IL216669A0 (en) 2012-02-29
TWI494125B (zh) 2015-08-01
AU2010256461A1 (en) 2012-01-12
HRP20161585T1 (hr) 2016-12-30
TW201544120A (zh) 2015-12-01
CA2764374C (en) 2019-11-19
US20100310602A1 (en) 2010-12-09
CY1118347T1 (el) 2017-06-28
US20140322268A1 (en) 2014-10-30
US20170182155A1 (en) 2017-06-29
TWI549688B (zh) 2016-09-21
JP2016028042A (ja) 2016-02-25
PT2437753T (pt) 2016-11-23
EP2437753B1 (en) 2016-08-31
RU2732574C2 (ru) 2020-09-21
US10632191B2 (en) 2020-04-28
CN105131051A (zh) 2015-12-09
CN105131051B (zh) 2020-07-10
RU2560182C2 (ru) 2015-08-20
US9814772B2 (en) 2017-11-14
AU2010256461B2 (en) 2016-03-17
IL242992B (en) 2018-01-31
EP3124491A1 (en) 2017-02-01
JP5830015B2 (ja) 2015-12-09
TW201102085A (en) 2011-01-16

Similar Documents

Publication Publication Date Title
LT2437753T (lt) Sintetiniai gliukopiranozillipidų adjuvantai ir juos turinčios vakcinų kompozicijos
LT2475384T (lt) Naujos vakcinos kompozicijos, apimančios saponino turinčius adjuvantus
IL223206A0 (en) Vaccine formulations
IL217166A0 (en) Vaccines and compositions against stretococcus pneumoniae
GB0703369D0 (en) Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines
GB201015132D0 (en) Vaccine composition
EP2285405A4 (en) VACCINE COMPOSITIONS AND METHODS
HK1213594A1 (zh) 免疫原性組合物及其用途
GB201005625D0 (en) Immunogenic proteins and compositions
EP2515940A4 (en) IMMUNOGENIC COMPOSITIONS AND CORRESPONDING METHODS
GB201103423D0 (en) Immunogenic proteins and compositions
EP2334332A4 (en) NEW COMPOSITIONS AND NEW ADJUVANTS
IL214211A0 (en) Stable vaccine compositions and methods for preparing the same
ZA201202968B (en) Adjuvanted vaccine formulations
EP2252326A4 (en) VACCINE COMPOSITIONS
IL214127A0 (en) Vaccine compositions
HK1177138A1 (en) Vaccine compositions based on sticholysin encapsulated in liposomes
IL220308A0 (en) Vaccine compositions
EP2337847A4 (en) ADJUVANTS FOR VACCINES
PL2190475T3 (pl) Sposoby poprawy właściwości adiuwancyjnych kompozycji szczepionek
AU2010904060A0 (en) Immunostimulatory and vaccine compositions
AU2010901997A0 (en) Immunostimulatory and vaccine compositions
EP2777712A4 (en) AUXILIARY SUBSTANCES FOR POLYSACCHARIDIVES AND FORMULATIONS OBTAINED THEREFROM
GB0900943D0 (en) Vaccine compositions
GB0912666D0 (en) Vaccine formulation